Deep Dive Digital Magazine

Managing Editor – Linda Banks 

The Deep Dive Digital Magazine has fresh content on pharma and healthcare industry trends in an innovative and interactive layout.

Content can be written for you by pharmaphorum or supplied by you. We also offer responsive banner advertising through the journal within all non-paid content or a Deep Dive issue sponsorship. All options include a dedicated support marketing plan for 2 months post publication.

Want to get involved? Contact Adam Jeffery at +44 (0)1932 339 263,

Deep Dive Patient Centricity 2 publication featured on a tablet device

Patient Centricity II

The phrase ‘patient centricity’ has been a buzzword for some time in the industry, but how many companies are merely paying it lip service? Are there firms that truly understand and have taken steps to reorganise their approach, internally and externally?

Though patient organisations and charities may feel pharma has a long way to go, this edition of Deep Dive features many examples where companies have listened and partnerships have resulted in improvements to patients’ lives – and pharma’s bottom line.

Read this issue for advice from the experts on how to define patient centricity, build trust and develop strong relationships.

Read Magazine


Our future Deep Dives:

April 2018: Patient Centric Health
May 2018: Future Pharma
July 2018: Oncology
September 2018: Market Access
November 2018: Innovation (including a focus on Start-ups)
December 2018/January 2019: Digital

Want to get involved? Contact Adam Jeffery at +44 (0)1932 339 263,

Deep Dive Digital 2 publication on tablet device

Digital II

There are an increasing number of digital companies with solutions entering the healthcare sector. These digital companies capture and analyse data, that can be used to improve clinical trial recruitment to real-world outcomes.

Patients and healthcare providers have technology to monitor symptoms and drug benefits over time. This is thanks to the abilities of hand-held and wearable devices.

Some pharma companies are blending digital into their company processes and others do not know where to start. This Deep Dive edition hears from the experts about how to navigate the challenges that still remain. There are some highlights of the companies and organisations shaking up the health space.

Deep Dive: Digital II

Deep Dive Market Access 2 publication on tablet device

Market Access II

Ultimately, market access is about ensuring effective treatments reach the people who need them. There are many components that must fit together along that journey, as explored by our expert contributors in this edition.

Just some of the themes include: the real impact of a Health Technology Assessement (HTA) decision, the promise of the ‘MINT’ countries (Mexico, Indonesia, Nigeria and Turkey), a step-by-step guide to the generation and use of real-world data, filling the gap between drug development and implementation, the pivotal role of Pharmacy Benefit Managers in the US, as well as the challenges in improving rare disease treatment and biosimilars uptake.

Deep Dive: Market Access II

Future Pharma July 17

Healthcare is facing transformation – tech companies large and small are moving in to the sector and, in turn, pharma is partnering with tech companies to develop novel solutions for patient monitoring, adherence, improving clinical trials, big data analysis, and recording the real-world effects of therapies, to name just a few. Add proactive patients and tailored drug advances and the future looks both exciting and uncertain.

This edition of Deep Dive considers topics ranging from pharmacogenomics and regenerative medicine to the growing importance of the behavioural sciences to current applications for artificial intelligence (AI), augmented reality (AR), virtual reality (VR) and bioelectronics.

Deep Dive: Future Pharma

Oncology May 17

Advances in treatments are revolutionising cancer management. But with one in two people likely to be diagnosed with the disease today, are screening and diagnosis swift enough and, for those needing treatment, how effective are the latest tailored drugs?

With more people living longer with cancer, is the wider support infrastructure for patients and carers adequate? And when is the right time for some to stop trying one more drug and focus on quality end-of-life care

This edition examines the latest immuno-oncology techniques, the question of affordability, and the cutting-edge research being funded by Cancer Research UK’s Grand Challenge programme.

Deep Dive: Oncology

Patient Centricity March 17

What does ‘patient centricity’ really mean? And what does it look like in practice? Can embedding a person-centred approach in an organisation be a win for the company as well as the patient?

The European Patients Forum, European Society for Person Centred Healthcare, Findacure and the EMA’s Patients’ and Consumers’ Working Party, outline examples of best practice and areas for further development, while home care service providers, market researchers and consultants offer expertise in developing patient support programmes, gathering reliable patient insights and examining whether the plethora of health-related apps are both used and of value.

Deep Dive: Patient Centricity

Digital November 16

This issue examines the use of digital technologies in the healthcare space, ranging from management of data and real-world evidence, to industry initiatives, to best practice in social media for optimal marketing and sales, plus how to get the most from gamification and scientific animation.

Read the views of some of the top minds in the field, from companies and organisations including IBM Watson Health, Twitter, the ABPI and EACA, and learn what’s next in the digital revolution.

Deep Dive: Digital

Market Access July 16

This issue brings you intelligent insights on the topic of market access in a series of in-depth articles and opinion pieces from industry thought leaders, patient group experts and our pharma journalists.

Read a keynote from EFPIA’s director general on how the industry is willing to partner with payers to deliver outcomes-driven, sustainable healthcare and overcome the challenges of rising demand from ageing populations and chronic diseases, hear about new models for improved access, and the specific needs of rare disease communities.

Deep Dive: Market Access

Close in 10 seconds